白蛋白尿与GFR变化作为早期CKD临床试验终点
美国FDA与欧洲EMA目前考虑将30%至40%的GFR下降作为肾衰竭的替代终点,但可能不适用于早期肾病。2018年3月,美国国家肾脏基金会与FDA、EMA合作举办科学研讨会,评估白蛋白尿或GFR变化作为候选替代终点。基于队列研究、临床试验的荟萃分析及试验设计模拟,结论认为早期白蛋白尿变化和GFR斜率均符合替代终点标准,但GFR变化的支持证据更强。
要点
- 早期白蛋白尿变化和GFR斜率可作为CKD进展临床试验的替代终点。
- GFR斜率作为终点的支持证据强于白蛋白尿变化。
- 使用替代终点需明确其性能良好的条件并限制适用场景。
核心结论
- 早期白蛋白尿变化和GFR斜率在特定条件下均符合替代终点标准,可用于CKD进展临床试验,但GFR变化的支持证据更强。
研究设计与样本
- 美国国家肾脏基金会与FDA、EMA合作举办科学研讨会,基于队列研究荟萃分析、临床试验荟萃分析及试验设计模拟三种平行工作。
主要发现
- 在队列研究中,校正测量误差后,UACR变化或eGFR斜率与肾脏病进展临床结局的关系强且一致。
- 在试验中,早期UACR变化对治疗效应的后验中位R2为0.47(95% BCI,0.02-0.96);基线UACR>30mg/g时限制后为0.72(95% BCI,0.05-0.99)。
- 3年总eGFR斜率的后验中位R2为0.97(95% BCI,0.78-1.00),慢性eGFR斜率(排除基线后前3个月)为0.96(95% BCI,0.63-1.00)。
- UACR降低30%或eGFR斜率每年减少0.5至1.0mL/min/1.73m2,在队列和试验中与临床结局的HR约为0.7。
- 模拟显示,当基线eGFR高、治疗效应均匀且无急性效应时,使用GFR斜率作为终点可大幅减少所需样本量和随访时间。
关键数值与推荐
- FDA和EMA目前愿意在适当条件下考虑将30%至40%的GFR下降作为肾衰竭的替代终点。
- 早期UACR变化对临床结局治疗效应的后验中位R2为0.47(95% BCI,0.02-0.96),限制基线UACR>30mg/g时为0.72(95% BCI,0.05-0.99)。
- 3年总eGFR斜率的后验中位R2为0.97(95% BCI,0.78-1.00),慢性eGFR斜率为0.96(95% BCI,0.63-1.00)。
- UACR降低30%或eGFR斜率每年减少0.5至1.0mL/min/1.73m2,与临床结局的HR约为0.7。
临床怎么用
- 在早期CKD临床试验中,可考虑使用早期白蛋白尿变化或GFR斜率作为替代终点,但需明确适用条件并限制使用场景。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) are currently willing to consider a 30% to 40% glomerular filtration rate (GFR) decline as a surrogate end point for kidney failure for clinical trials of kidney disease progression under appropriate conditions. However, these end points may not be practical for early stages of kidney disease. In March 2018, the National Kidney Foundation sponsored a scientific workshop in collaboration with the FDA and EMA to evaluate changes in albuminuria or GFR as candidate surrogate end points. Three parallel efforts were presented: meta-analyses of observational studies (cohorts), meta-analyses of clinical trials, and simulations of trial design. In cohorts, after accounting for measurement error, relationships between change in urinary albumin-creatinine ratio (UACR) or estimated GFR (eGFR) slope and the clinical outcome of kidney disease progression were strong and consistent. In trials, the posterior median R2 of treatment effects on the candidate surrogates with the clinical outcome was 0.47 (95% Bayesian credible interval [BCI], 0.02-0.96) for early change in UACR and 0.72 (95% BCI, 0.05-0.99) when restricted to baseline UACR>30mg/g, and 0.97 (95% BCI, 0.78-1.00) for total eGFR slope at 3 years and 0.96 (95% BCI, 0.63-1.00) for chronic eGFR slope (ie, the slope excluding the first 3 months from baseline, when there might be acute changes in eGFR). The magnitude of the relationships of changes in the candidate surrogates with risk for clinical outcome was consistent across cohorts and trials: a UACR reduction of 30% or eGFR slope reduction by 0.5 to 1.0mL/min/1.73m2 per year were associated with an HR of ∼0.7 for the clinical outcome in cohorts and trials. In simulations, using GFR slope as an end point substantially reduced the required sample size and duration of follow-up compared with the clinical end point when baseline eGFR was high, treatment effects were uniform, and there was no acute effect of the treatment. We conclude that both early change in albuminuria and GFR slope fulfill criteria for surrogacy for use as end points in clinical trials for chronic kidney disease progression under certain conditions, with stronger support for change in GFR than albuminuria. Implementation requires understanding conditions under which each surrogate is likely to perform well and restricting its use to those settings.
引用
- Levey AS, Gansevoort RT, Coresh J, et al. Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency. Am J Kidney Dis. 2019. PMID: 31473020. doi:10.1053/j.ajkd.2019.06.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。